蘑法生技致力於生醫蛋白質研發及生產，從靈芝選殖小孢子靈芝免疫調節蛋白質(FIP-GMI)，成為第一個成功進入國際市場的真菌免疫調節蛋白，擁有多項專利及科學研究，應用跨足醫藥(MM767593)、保健品(Reishimmune®)、化妝品(Lumiderma®)及寵物食品(New RS Protein®)。GMI微量有效，可在體內擔當指揮官，下指令調控體內細胞的運作，達到多種生理功效。 最新發現 GMI 能抑制冠狀病毒感染，且降低細胞激素風暴與其可能引起的中重症，並於今年阿基米德發明展勇奪金牌，為大眾提供一層安全的隱型防護。

MycoMagic Biotech. is committed to unlocking the biomedical protein, FIP-GMI, for decades. Our strategy is to strive for the innovative product as a solution applied from pharmaceutical (MM767593), nutraceutical (Reishimmune®), cosmetics (Lumiderma®) to pet food (New RS Protein®). GMI has been shown to alleviate COVID-19 infection and the potential severe cases led by the cytokine storm. This work won a gold medal in the Moscow International Salon of Industrial Property “Archimedes” this year.

影片提供：Taiwan Bio